What 2ml of Semaglutide Actually Tells You About Your Dose

What the trial data tells us about semaglutide concentration and dosing precision

The STEP 1 trial, published in the New England Journal of Medicine, randomised over 1,900 adults with obesity to 68 weeks of once-weekly semaglutide 2.4mg versus placebo. Average body-weight reduction at that maintenance dose was around 15%. That precision (a specific milligram figure, not a volume) is the basis on which semaglutide is licensed, studied and prescribed.

The reason this matters for anyone searching '2ml of semaglutide' is straightforward. Concentration varies. A 0.25mg Wegovy pen and a 2.4mg Wegovy pen both contain 2ml of solution, but the amount of active semaglutide dissolved in that solution is quite different. Quoting volume alone tells a clinician almost nothing useful; quoting milligrams per millilitre, or the total milligrams per pen, tells them everything. If you've seen '2ml' on a box or a prescription, it confirms the pen's fill volume, not what dose you're on.

The NHS medicines page for semaglutide describes the full Wegovy schedule and explains how each strength works within the titration pathway. That's the clearest patient-level reference for understanding the relationship between what's in the pen and what your body receives each week.

How 2ml of semaglutide solution maps to each step of the Wegovy schedule

Wegovy's licensed titration runs: 0.25mg, then 0.5mg, then 1.0mg, then 1.7mg, reaching 2.4mg as the standard maintenance dose, each step held for roughly four weeks before the prescriber considers moving up. The higher 7.2mg dose, approved by the MHRA in early 2026, follows the same graduated approach with the prescriber in the lead.

At every step, the pen contains 2ml. What changes is the concentration of semaglutide per millilitre. This is standard pharmaceutical practice: manufacturers fix the fill volume and adjust concentration rather than producing pens of wildly different sizes. It keeps device design consistent and reduces injection errors. So if someone describes their pen as containing '2ml semaglutide', that phrase is accurate but incomplete, the strength printed on the label is the clinically relevant figure.

For a fuller picture of how the different licensed strengths sit within the treatment pathway, our semaglutide overview walks through the mechanism, the schedule, and what to expect at each stage. And if you're curious about a specific dose level in more detail, the pages covering semaglutide 1mg and semaglutide 2mg go deeper on those particular points in the ladder.

Why this distinction matters, and what it doesn't change about how treatment works

We hear this question from people who've been prescribed Wegovy privately, who are considering transferring from another provider, or who've spotted the volume on a prescription and felt uncertain whether they're getting the right amount. That uncertainty is completely understandable. The labelling on injectable medicines can look technical and unfamiliar, especially if you've never used a pre-filled pen before.

The practical answer is this: if your pen is labelled with the strength your prescriber intended (say, 0.5mg or 1.0mg) and contains 2ml of solution, that is exactly what the manufacturer designed it to contain. You inject once a week, at the same day and time, following the instructions in the Patient Information Leaflet. The volume drawn into the injection mechanism by the pen itself is preset; you don't measure millilitres.

What a prescriber assesses before moving you to a higher strength is your response to treatment, your side-effect profile and your clinical history, not the volume in the pen. For context on how Wegovy fits into the broader private treatment landscape, our Wegovy treatment page covers eligibility, the MHRA-licensed indications, and what the consultation process involves. There's also a useful read on semaglutide's half-life if you're thinking about timing, missed doses or switching, those questions belong with your prescriber and the Patient Information Leaflet, but understanding the pharmacokinetics helps frame them.

Private access, clinical review and what to do next

Wegovy is a prescription-only medicine. In the UK, the only lawful route to obtaining it is through a prescriber who has assessed your clinical suitability. On the NHS, access is routed through specialist weight management services under NICE guidance TA875, and waiting lists can be long. Private treatment through a regulated online pharmacy is the practical alternative for people who don't meet NHS criteria yet or prefer not to wait.

At nume, every consultation is read and decided by a GPhC-registered Independent Prescriber, a real clinician, same day. Our pharmacy holds GPhC premises registration 9012878, verifiable on the regulator's register. Medicines are sourced through the licensed UK supply chain. If you'd like to explore whether treatment is appropriate for you, or if you're an existing patient with questions about your dose, our treatment consultation page is the right starting point. You can also read more about how to access Wegovy through a regulated UK pharmacy before you begin.